Residency · Residency · Interventional Radiology

Acute Limb Ischemia: Catheter-Directed Thrombolysis

Definition and Epidemiology

Acute limb ischemia (ALI) refers to a sudden decrease in limb perfusion that threatens limb viability, typically within 14 days of symptom onset. The condition affects approximately 1.5 per 10,000 persons per year. The underlying cause is most often either embolism or in situ thrombosis. Embolism accounts for 30 to 40 percent of cases and usually arises from a cardiac source such as atrial fibrillation, mural thrombus, or valvular disease, though paradoxical embolism and aortic plaque can also be responsible. Thrombosis in situ makes up 40 to 50 percent and typically involves acute thrombosis of an atherosclerotic plaque, stent or graft thrombosis, or popliteal aneurysm thrombosis. Less common causes include trauma, dissection, hypercoagulable states, and iatrogenic injury following catheterization.

Clinical Presentation: The 6 Ps

The classic presentation of ALI is described by the six Ps. Pain is usually sudden in onset and severe, often centered in the foot and calf. Pallor manifests as a white or mottled appearance. Pulselessness refers to absent distal pulses. Poikilothermia describes a cool extremity. Paresthesia, or sensory loss, signals advancing ischemia. Paralysis, a motor deficit, indicates severe ischemia and imminent tissue loss.

Rutherford Classification of Acute Limb Ischemia

Categories

The Rutherford classification stratifies ALI into four categories that directly guide management. Category I (Viable) describes a limb with no sensory or motor deficit and audible arterial Doppler signals; it is not immediately threatened and allows time for a full workup. Category IIa (Marginally Threatened) involves minimal sensory loss limited to the toes with no motor deficit; arterial Doppler signals are often inaudible but venous signals remain, and the limb is salvageable with prompt treatment. Category IIb (Immediately Threatened) presents with sensory loss extending beyond the toes, rest pain, and mild to moderate motor deficit; arterial Doppler signals are inaudible though venous signals persist, and immediate revascularization is required. Category III (Irreversible) is characterized by profound anesthesia and paralysis with no Doppler signals at all; major tissue loss is inevitable and primary amputation is indicated.

Diagnostic Workup

Clinical assessment and Rutherford classification should be the first priority. In Category IIb patients, revascularization should not be delayed for extensive imaging. CT angiography is rapid and widely available, confirming the level of occlusion, distinguishing embolic from thrombotic etiology, and assessing distal runoff. Duplex ultrasound can provide bedside confirmation of the occlusion level but is limited in the emergency setting. Catheter angiography, the gold standard for anatomic detail, is typically performed at the time of intervention. Laboratory studies should include a complete blood count, comprehensive metabolic panel, coagulation studies, creatine kinase for baseline reperfusion injury monitoring, lactate, and a type and screen.

Catheter-Directed Thrombolysis (CDT)

Principle

Catheter-directed thrombolysis involves infusing a fibrinolytic agent directly into the thrombus via an endovascular catheter. This approach maximizes local drug concentration at the thrombus while minimizing the systemic fibrinolytic effect. CDT is best suited for Category I and IIa ALI and select Category IIb cases.

Agents

Alteplase (tPA) is the most commonly used agent, typically infused at 0.5 to 1.0 mg per hour for a maximum duration of 24 to 48 hours. Tenecteplase has a longer half-life and may be given as a pulse-spray bolus followed by infusion; its use is increasing. Reteplase offers an intermediate half-life and is employed at some centers. Urokinase was historically the standard but is now less available.

Technique

Arterial access is obtained, most commonly via contralateral retrograde femoral puncture for lower extremity ALI. A diagnostic angiogram defines the occlusion anatomy. The occlusion is crossed with a guidewire, and a multi-sidehole infusion catheter or infusion wire is embedded within the thrombus. Lytic infusion is initiated along with concurrent heparin through the sheath, typically at a subtherapeutic dose of 500 units per hour. The patient is monitored in the ICU during infusion: fibrinogen is checked every six hours and the lytic is held if fibrinogen drops below 150 mg/dL. PTT, clinical exam, and the access site are also monitored. The patient returns to the angiography suite at 12 to 24 hour intervals for check angiography. Once the thrombus is cleared, any underlying lesion such as a stenosis or aneurysm is treated to prevent recurrence.

Pharmacomechanical Thrombectomy (PMT)

Pharmacomechanical thrombectomy combines mechanical thrombus removal with lytic agents to accelerate treatment. The AngioJet (rheolytic system) uses power pulse spray to deliver lytic agent into the thrombus followed by aspiration and can achieve single-session results. Aspiration-based systems such as the Aspirex and Indigo platforms provide direct mechanical thrombectomy. The EKOS system uses ultrasound energy to accelerate fibrinolytic penetration into the thrombus. The advantages of PMT include faster lysis, shorter ICU stays, and potentially reduced bleeding complications. Data from the PEARL registry and other sources support PMT as a viable alternative to overnight CDT.

Surgical Thrombectomy

Fogarty balloon embolectomy is the standard surgical approach for embolic ALI and is preferred in Category IIb patients with motor deficits, where the time-sensitive nature of the ischemia precludes prolonged lysis. Open thrombectomy combined with intraoperative thrombolysis is another option. When underlying occlusive disease is present, bypass grafting may be required.

Key Trials and Evidence

STILE Trial (1994)

The STILE trial compared CDT with surgery for ALI and acute-on-chronic ischemia. CDT had a higher 30-day composite endpoint, driven by ongoing ischemia, but subgroup analysis demonstrated a benefit for acute ischemia of less than 14 days duration. Surgery proved more effective for chronic occlusions lasting longer than 14 days.

TOPAS Trial (1998)

The TOPAS trial randomized patients with ALI of less than 14 days to urokinase CDT versus surgical revascularization. Amputation-free survival was similar at 6 and 12 months. The CDT group experienced higher bleeding complications but benefited from the identification of underlying lesions that could then be treated with less-invasive approaches.

Rochester Series and Meta-Analyses

No clear survival advantage of CDT over surgery has been demonstrated in meta-analyses. The primary value of CDT lies in reducing the extent of surgery needed. Patient selection is paramount: CDT works best for embolic ALI in Category I to IIa and select IIb presentations.

Reperfusion Injury and Compartment Syndrome

Reperfusion following revascularization releases toxic metabolites including potassium, myoglobin, lactate, and free radicals. Reperfusion syndrome can manifest as hyperkalemia, metabolic acidosis, myoglobinuria, and acute kidney injury. Compartment syndrome occurs when muscle swelling within the fascial compartments elevates pressures enough to cause further ischemia. Clinical signs include pain out of proportion, pain with passive stretch, and tense compartments. The treatment is four-compartment fasciotomy, and prophylactic fasciotomy should be considered after prolonged ischemia exceeding six hours. Creatine kinase levels, urine output, potassium, and renal function should be monitored closely after revascularization.

Complications of CDT

Major bleeding occurs in 5 to 15 percent of cases, with intracranial hemorrhage in less than 1 to 2 percent. Distal embolization can result from fragmentation of thrombus during lysis. Access site complications include hematoma and pseudoaneurysm. Reperfusion injury, as described above, is an additional concern. Contraindications to CDT include recent surgery or trauma within 14 days, active internal bleeding, recent cerebrovascular accident within 3 months, and intracranial pathology.

<image>Flowchart for management of acute limb ischemia. Starting with clinical assessment and Rutherford classification (I, IIa, IIb, III), branching into management pathways: Category I leads to anticoagulation and elective workup; Category IIa leads to catheter-directed thrombolysis or pharmacomechanical thrombectomy; Category IIb leads to emergent surgical thrombectomy or hybrid approach; Category III leads to primary amputation. Arrows show decision points including imaging (CTA), time to intervention, and underlying lesion treatment after thrombus clearance.</image>

<image>Illustration of catheter-directed thrombolysis technique for acute lower extremity arterial occlusion. Sequential panels showing: (1) Angiogram demonstrating acute occlusion of the superficial femoral artery with absent distal flow; (2) Guidewire traversing the thrombus with a multi-sidehole infusion catheter embedded within the clot, showing lytic agent being infused through the sideholes; (3) Check angiogram at 12-24 hours showing partial thrombus dissolution revealing an underlying stenosis; (4) Final angiogram after balloon angioplasty of the underlying lesion with restored flow to the trifurcation vessels. Labels indicate the infusion catheter, thrombus, and underlying lesion.</image>

<image>Cross-sectional diagram of lower leg compartment syndrome following reperfusion. An axial view of the mid-calf showing the four compartments (anterior, lateral, superficial posterior, deep posterior) with swollen muscles compressing neurovascular structures. The anterior tibial artery, posterior tibial artery, peroneal artery, deep peroneal nerve, and tibial nerve are labeled. An inset shows the fasciotomy incision sites (medial and lateral) with arrows indicating decompression of all four compartments.</image>

Clinical Pearls

The Rutherford classification drives management: Category IIb patients need the operating room, not the angiography suite for prolonged CDT. During CDT infusion, fibrinogen levels must be checked regularly, and the lytic should be held if fibrinogen drops below 150 mg/dL to reduce hemorrhagic risk. Embolic ALI, characterized by the absence of antecedent claudication, presence of atrial fibrillation, and a sharp cutoff on imaging, may respond faster to CDT and carries a better prognosis than thrombotic ALI. After clearing thrombus, always look for an underlying lesion such as a stenosis or aneurysm that precipitated the thrombosis, because treating it prevents recurrence. Teams should be prepared for reperfusion injury with protocols for hyperkalemia and acidosis and should monitor closely for compartment syndrome. Neurovascular status should be documented before and after every intervention.

References

• Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity (STILE trial). Ann Surg 1994
• Thrombolysis or peripheral arterial surgery (TOPAS) trial. J Vasc Surg 1998
• Defined by the Defined by the SVS/SIR guidelines on catheter-directed thrombolysis for ALI. J Vasc Interv Radiol 2010
• Defined by the ESVS Guidelines on the management of acute limb ischemia. Eur J Vasc Endovasc Surg 2020

Read this lecture as Markdown